abstract |
FIELD: medicine. n SUBSTANCE: invention is an antibody to Epiregulin that contains a variable region of the heavy chain comprising the heavy chain CDR1 of the sequence of SEQ ID NO: 9, the heavy chain CDR2 of SEQ ID NO: 160 and the heavy chain CDR3 of SEQ ID NO: 158; and the light chain variable region comprising the light chain CDR1 of SEQ ID NO: 163, the light chain CDR1 of SEQ ID NO: 13 and the light chain CDR3 of SEQ ID NO: 164, which comprises a variable region of the heavy chain corresponding to the heavy chain variable region of SEQ ID NO: 150, and a light chain variable region corresponding to the variable region of SEQ ID NO: 141; the heavy chain constant region of SEQ ID NO: 30, which contains the light chain constant region of SEQ ID NO: 27, has neutralizing activity, cytotoxicity, where the cytotoxicity is CDC and/or ADCC. n EFFECT: invention inhibits cancer cells growth by expression of cytotoxic activity and neutralizing activity against Epiregulin-expressing cancer cells. n 7 cl, 23 tbl, 21 dwg, 19 ex |